Literature DB >> 25873202

Expression of hMOF, but not HDAC4, is responsible for the global histone H4K16 acetylation in gastric carcinoma.

Lin Zhu1, Jiaxing Yang2, Linhong Zhao1, Xue Yu1, Lingyao Wang1, Fei Wang1, Yong Cai1, Jingji Jin1.   

Abstract

Increasing evidence suggests that the alteration of global histone H4K16 acetylation (H4K16ac) may be involved in several types of cancer. It is known that the global histone H4K16ac level in cells is controlled by several enzymes including histone acetyltransferases (HATs) and histone deacetylases (HDACs). We report in detail which particular enzyme is responsible for global reduction of histone H4K16ac in gastric cancer. Our study included 156 frozen tissue samples of primary diagnosed gastric cancer tissues and matched adjacent or normal tissues, and the gastric cancer cells SGC-7901 and MGC-803. The reverse transcription polymerase chain reaction (RT-PCR), western blot, transient transfection and siRNA knockdown approaches were used. Statistical analysis of the qRT-PCR data revealed that a significant reduction (>2-fold decreased) of hMOF expression in gastric cancer tissues in 81% (42/52) of patients. In patients with gastric cancer, downregulation of hMOF was connected to gastric cancer and tissues with pT2-T4 tumor status, lymph node metastasis and distant metastasis. Overall survival rates revealed a significant difference between the low- and high-hMOF expression groups. However, there was no significant difference by age, gender and cell differentiation. In SGC-7901 and MGC-803 gastric cancer cells, as expected, low expression of hMOF and decreased global histone H4K16ac were observed. Although we did not obtained a statistically significant high-level of HDAC4 in tumor tissues, increased HDAC4 in both gastric cancer cell lines was detected. Therefore, overexpression of hMOF and knockdown of HDAC4 experiments were carried out to investigate the potential coordinating role between hMOF and HDAC4 on global histone H4K16ac in gastric cancer. Overexpression of hMOF increased global H4K16ac in cells, however, no obvious increase of global H4K16ac in HDAC4 knockdown MGC-803 cells was observed. Histone acetyltransferase hMOF and global histone H4K16ac status might be involved in gastric cancer tumorigenic pathways. hMOF, but not HDAC4, is mainly responsible for global histone H4K16ac acetylation in gastric cancer cells.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25873202     DOI: 10.3892/ijo.2015.2956

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  15 in total

Review 1.  Global histone post-translational modifications and cancer: Biomarkers for diagnosis, prognosis and treatment?

Authors:  Shafqat Ali Khan; Divya Reddy; Sanjay Gupta
Journal:  World J Biol Chem       Date:  2015-11-26

2.  Structure and function of histone acetyltransferase MOF.

Authors:  Qiao Yi Chen; Max Costa; Hong Sun
Journal:  AIMS Biophys       Date:  2015-10-19

Review 3.  Histone Acetyltransferase MOF Orchestrates Outcomes at the Crossroad of Oncogenesis, DNA Damage Response, Proliferation, and Stem Cell Development.

Authors:  Mayank Singh; Albino Bacolla; Shilpi Chaudhary; Clayton R Hunt; Shruti Pandita; Ravi Chauhan; Ashna Gupta; John A Tainer; Tej K Pandita
Journal:  Mol Cell Biol       Date:  2020-08-28       Impact factor: 4.272

4.  Strong Correlation between the Expression Levels of HDAC4 and SIRT6 in Hematological Malignancies of the Adults.

Authors:  Zsuzsanna Gaál; Éva Oláh; László Rejtő; Ferenc Erdődi; László Csernoch
Journal:  Pathol Oncol Res       Date:  2016-10-20       Impact factor: 3.201

Review 5.  The many lives of KATs - detectors, integrators and modulators of the cellular environment.

Authors:  Bilal N Sheikh; Asifa Akhtar
Journal:  Nat Rev Genet       Date:  2019-01       Impact factor: 53.242

Review 6.  The Functional Analysis of Histone Acetyltransferase MOF in Tumorigenesis.

Authors:  Jiaming Su; Fei Wang; Yong Cai; Jingji Jin
Journal:  Int J Mol Sci       Date:  2016-01-14       Impact factor: 5.923

7.  Chromatin regulation by Histone H4 acetylation at Lysine 16 during cell death and differentiation in the myeloid compartment.

Authors:  Rocio G Urdinguio; Virginia Lopez; Gustavo F Bayón; Rafael Diaz de la Guardia; Marta I Sierra; Estela García-Toraño; Raúl F Perez; María G García; Antonella Carella; Patricia C Pruneda; Cristina Prieto; Marija Dmitrijeva; Pablo Santamarina; Thalía Belmonte; Cristina Mangas; Elena Diaconu; Cecilia Ferrero; Juan Ramón Tejedor; Juan Luis Fernandez-Morera; Cristina Bravo; Clara Bueno; Alejandra Sanjuan-Pla; Ramon M Rodriguez; Beatriz Suarez-Alvarez; Carlos López-Larrea; Teresa Bernal; Enrique Colado; Milagros Balbín; Olivia García-Suarez; María Dolores Chiara; Inés Sáenz-de-Santa-María; Francisco Rodríguez; Ana Pando-Sandoval; Luis Rodrigo; Laura Santos; Ana Salas; Jesús Vallejo-Díaz; Ana C Carrera; Daniel Rico; Inmaculada Hernández-López; Amparo Vayá; José M Ricart; Edward Seto; Núria Sima-Teruel; Alejandro Vaquero; Luis Valledor; Maria Jesus Cañal; David Pisano; Osvaldo Graña-Castro; Tim Thomas; Anne K Voss; Pablo Menéndez; Ana Villar-Garea; Rainer Deutzmann; Agustín F Fernandez; Mario F Fraga
Journal:  Nucleic Acids Res       Date:  2019-06-04       Impact factor: 16.971

Review 8.  The non-specific lethal (NSL) complex at the crossroads of transcriptional control and cellular homeostasis.

Authors:  Bilal N Sheikh; Sukanya Guhathakurta; Asifa Akhtar
Journal:  EMBO Rep       Date:  2019-06-03       Impact factor: 8.807

Review 9.  Mass spectrometry-based characterization of histones in clinical samples: applications, progress, and challenges.

Authors:  Roberta Noberini; Giulia Robusti; Tiziana Bonaldi
Journal:  FEBS J       Date:  2021-01-23       Impact factor: 5.622

10.  The adenoviral E1A N-terminal domain represses MYC transcription in human cancer cells by targeting both p300 and TRRAP and inhibiting MYC promoter acetylation of H3K18 and H4K16.

Authors:  Ling-Jun Zhao; Paul M Loewenstein; Maurice Green
Journal:  Genes Cancer       Date:  2016-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.